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Abstract
Background: It is known that Hashimoto’s thyroiditis (HT) may progress to Graves’ disease (GD) and that this
phenomenon may be more frequent in the patients with Down syndrome (DS).
Aims: To shed light on the relationships between Down syndrome (DS) and metamorphic thyroid autoimmunity.
Patients and Methods: We reconstructed the conversion process from HT to GD in 12 DS children. All the data
recorded at HT diagnosis and throughout the time interval from entry to GD presentation were retrospectively
taken from patients’ files, as well as those recorded at GD diagnosis and during the subsequent evolution.
From GD diagnosis all patients underwent methimazole treatment, at a dose that was adjusted on the basis of
clinical findings and thyroid tests.
Results: Time interval between HT and GD was not different in the seven patients who received during that time a
L-thyroxine (L-T4) treatment than in those who were not treated. After methimazole onset all patients exhibited a
prolonged remission of hyperthyroidism. In 8/12 patients this treatment is still being continued 2–7 years after its
initiation. The mean methimazole dosage needed to maintain euthyroidism in these eight patients was 0.12 ±
0.02 mg/kg/day.
In the remaining four patients methimazole was withdrawn from 1.9 to 7 years after its initiation and no relapses
were recorded 2.0–2.1 years after its withdrawal. These patients developed, 0.1–0.3 years after methimazole
withdrawal, a picture of overt hypothyroidism and needed treatment with L-T4, that is now being continued.
No patients needed non-pharmacological therapies.
Conclusions: 1) DS children might be incline to manifest over time a phenotypic metamorphosis from HT to GD
and to subsequently fluctuate from hyperthyroidism to hypothyroidism; 2) in DS GD may have a mild biochemical
and clinical course.
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Background
Hashimoto’s thyroiditis (HT) and Graves’ disease (GD)
are autoimmune thyroid disorders (AITDs) which are
caused by two distinct and separate paradigms [1] and
have been for a long time regarded as two different
disease entities. More recent views, in contrast, have
considered the hypothesis that these disorders might be
two sides of the same coin [2]. In fact, during the last
years, it has been sporadically reported that GD and HT
may follow one another in the same individuals, due to a
sequential phenotypic conversion from GD to HT [2, 3]
or viceversa [4–10].
The most common metamorphic scenario regards the
evolution from GD into HT, whereas the metamorphosis
from HT into GD seems to be less common. This is
probably due to the lack, in the individuals with long-
standing HT, of a critical mass of functioning thyroid
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tissue able to react to thyrotropin (TSH) receptor
antoantibodies (TRABs) [7].
Among the variables which seem to be able to condi-
tion the shifting process from HT into GD, it has been
recently reported that the association with either Turner
syndrome (TS) or Down syndrome (DS) might play
some predisposing role [11]. In fact, when compared
with HT children without these chromosomopathies,
those with TS- or DS- associated HT were found to be
at higher risk of progressing towards GD [11].
In the present study we have retrospectively recon-
structed the conversion process from HT to GD and the
subsequent evolution of GD in a series of 12 children
and adolescents with DS, in order to shed further light




For the present study, we took into consideration all the
children and adolescents with DS who were being
followed, during the period 2000–2010, in the pediatric
endocrinology centers of our Hospitals owing to a previ-
ous diagnosis of HT and developed throughout follow-
up a picture of GD.
The criteria for diagnosis of HT were: a) no
exophthalmos; b) hypoechogenic thyroid pattern at
ultrasonography (US) consistent with AITD; c) posi-
tivity for serum thyroglobulin and/or thyroid peroxid-
ase autoantibodies (TgAbs and TPOAbs, respectively)
at titers above the upper limits of the reference
ranges, as subsequently detailed; d) negativity for
TRABs (<1 IU/l).
The criteria for diagnosis of GD were: a) elevated free
thyroxine FT4 (>24.4 pmol/l) and suppressed TSH (<0.1
mU/l) serum levels; b) positivity for TRABs (>1.5 IU/l);
c) hypoechogenic thyroid pattern at US consistent with
AITD; d) no tendency to spontaneous normalization of
hyperthyroidism before methimazole treatment.
Study design
All the data recorded at HT diagnosis and at GD presen-
tation (median time interval 4.5 years, range 0.7–6.5)
were retrospectively reconstructed from patients’ files, as
well as those recorded during the subsequent evolution
from GD presentation onwards.
Since the time of GD diagnosis all the recruited pa-
tients underwent a pharmacological treatment with
methimazole, at a dose that was periodically adjusted
on the basis of clinical findings and thyroid function
tests. The median follow-up duration (from HT
diagnosis to the last examination) was 8.0 years
(range 5.7–10.1).
Methods
Serum concentrations of TSH (normal range 0.3–
4.5 mU/l) and FT4 (normal range 10.3–24.4 pmol/l)
were measured by radioimmunoassay methods.
Anti - TPOAbs and anti – TgAbs were measured by
electrochemiluminescence immunoassay methods. Ac-
cording to the employed methods values above 20 and
30 IU/ml, respectively, are defined as positive [12].
TRAB serum levels were measured by a second gener-
ation radioreceptor assay using the human recombinant
TSH receptor. According to the employed method,
values below 1.0 IU/l are defined as negative and values
above 1.5 IU/l as positive, whilst values between 1.0 and
1.5 IU/l are considered as questionably positive [13].
Thyroid US examinations for assessment of echogeni-
city were always performed by experienced ultrasonogra-
phers with high – resolution machines.
With regard to thyroid function patterns at diagno-
sis of both HT and GD, they were evaluated accord-
ing to FT4 and TSH serum levels and classified into
the following groups: 1) euthyroidism (both FT4 and
TSH within normal limits); 2) overt hypothyroidism
(low FT4 together with elevated TSH); 3) subclinical
hypothyroidism SH (normal FT4 as opposed to ele-
vated TSH); 4) hyperthyroidism (suppressed TSH, as
opposed to elevated FT4).
Statistical analysis
Results are expressed as mean ± SD or median and range
values, as appropriate. Comparisons between groups
were performed by Student’s unpaired t test (normally
distributed data) or Mann–Whitney U test (non-nor-
mally distributed data), as appropriate. Frequency rates
were compared by chi-square (χ2) test. Correlations be-
tween quantitative variables were assessed using
Pearson’s correlation analysis. The level of significance
was set at 0.05 for all the statistical assessments.
The study design was approved by the ethical commit-
tees of the hospitals participating in our study and the
patients or their parents gave informed consent. Appro-
priate consent was also obtained earlier from the Study
Group for thyroid diseases of the Italian Society for
Pediatric Endocrinology and Diabetology.
Results
The DS children and adolescents with the previous diag-
nosis of HT who developed, during follow-up, a picture
of GD were 12 (seven girls). Their ages at the times of
HT and GD diagnosis are reported in Table 1.
The main results are summarized in Table 1.
Only one patient had already entered puberty at HT
diagnosis (No.12 of Table 1), whilst all the remaining
ones were still prepubertal.
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At HT diagnosis only one patient was biochemically
euthyroid (No.12), whereas the other ones exhibited
different biochemical patterns of thyroid dysfunction:
either SH in seven cases (Nos. 1, 4, 5, 7, 8, 10, 11),
or overt hypothyroidism (No. 2), or hyperthyroidism
in three cases (Nos. 3, 6, 9), All patients showed ele-
vated serum levels of both TPOAbs and TgAbs, ex-
cept the case No. 10, whose TgAbs were within
normal range (Table 1). In accordance with our cri-
teria for diagnosis of HT, TRAB serum levels were
initially negative in all cases.
At HT diagnosis five patients with either overt
hypothyroidism (No.2) or SH and TSH level higher
than 8 mU/l (Nos. 4, 8, 10, 11 of Table 1) underwent
a treatment with L-thyroxine (L-T4), that was pro-
longed for 1.0–6.5 years (median 2.5), whereas no
pharmacological therapy was initially started in the
remaining seven cases.
In two additional cases, who were initially either eu-
thyroid (No. 12) or hyperthyroid (No. 6), a biochemical
picture of overt hypothyroidism became evident only
during the time interval between HT diagnosis and GD
presentation. This required a L–T4 therapy that was
prolonged in both cases for 1.0 year and was withdrawn
at the time of GD presentation (Table 1).
A family history of AITD was recorded in only two pa-
tients (Nos. 6 and 7). Extra-thyroidal autoimmune dis-
eases were detected in 5/12 children: celiac disease in
the cases Nos. 1, 2, 3, 7 and 12; type 1 diabetes in the
cases Nos. 1, 3 and 12; juvenile idiopathic arthritis in the
patient No. 12.
In the entire cohort time interval between HT diagno-
sis and GD presentation ranged from 0.7 to 6.5 years
(median 4.2). This time interval was not significantly dif-
ferent in the seven patients who had undergone L-T4
treatment than in those who had not been previously
Table 1 Sex, ages, thyrotropin (TSH), free thyroxine (FT4) and thyroid autoantibody serum levels in the 12 patients of our series at
diagnosis of both Hashimoto’s thyroiditis (HT) and Graves’ disease (GD)
Patients Sex Age (years) TSHa (mU/l) FT4b (pmol/l) TPOAbsc (IU/ml) TgAbsd (IU/ml) TRABse (IU/l)
1 F HT 3.0 7.10 12.6 95 60 <1.0
GD 5.5 0.0500 45.1 796 150 23.4
2 F HT 3.0 19.56 9.9 1310 182 <1.0
GD 9.0 0.0500 36.8 1300 79 19.0
3 F HT 3.3 0.07 24.6 57 187 <1.0
GD 4.0 0.0060 47.8 44 148 85.0
4 M HT 4.0 8.80 16.8 180 120 <1.0
GD 9.9 0.0500 66.1 278 199 32.7
5 F HT 4.0 5.30 12.1 26 28 <1.0
GD 8.8 0.0001 41.9 149 758 25.2
6 M HT 5.0 0.05 50.0 284 35 <1.0
GD 6.1 0.0500 41.6 189 170 22.0
7 F HT 5.9 5.10 17.4 75 302 <1.0
GD 11.1 0.0100 31.6 248 55 28.0
8 F HT 6.0 8.20 10.5 144 104 <1.0
GD 9.0 0.0500 26.0 39 3 21.0
9 M HT 8.0 0.01 38.0 278 199 <1.0
GD 10.0 0.0050 58.7 278 199 32.7
10 M HT 9.7 9.10 11.0 37 2 <1.0
GD 13.2 0.0200 29.4 200 200 23.0
11 M HT 10.0 8.10 10.5 22 119 <1.0
GD 15.0 0.0010 34.4 45 220 16.0
12 F HT 13.5 4.30 18.0 23 109 1.0
GD 20.0 0.0060 25.0 61 117 31.4
anormal range 0.3–4.5 bnormal range 10.3–24.4
cThyroid peroxidase autoantibodies (normal values <20)
dThyroglobulin autoantibodies (normal values <30)
eTSH receptor autoantibodies (normal values <1.0)
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treated. In those who had been treated no significant
correlation between L-T4 treatment duration and time
interval HT – GD was found.
At GD diagnosis hyperthyroid manifestations (tachy-
cardia and/or palpitations, tremor, weight loss, goiter)
were observed in 10/12 patients, but only three of them
exhibited exophthalmos (Nos. 4, 7 and 9 of Table 1).
TRAB serum concentrations at GD presentation did
not significantly correlate with the values of both
TPOAbs and TgAbs recorded at the time of HT diagno-
sis. Furthermore, TRAB serum levels were not signifi-
cantly different in the seven patients who had been
treated with L-T4 during the time interval HT-GD than
in those who had not been treated. In those who had
been treated no significant correlation between treat-
ment duration and TRAB serum levels was detected.
After the onset of methimazole treatment (at an initial
dosage of 0.38 ± 0.12 mg/kg/day, range from 0.25 to
0.53) all the patients exhibited, at varying time intervals,
a prolonged clinical and biochemical remission of hyper-
thyroidism picture. In 8/12 patients (Nos. 2, 4, 5, 7, 8, 9,
11 and 12 of Table 1) this treatment is still being contin-
ued 2–7 years after its initiation (median 2.6 years). The
methimazole dosage needed to maintain euthyroidism in
these eight patients currently ranges from 0.10 to
0.15 mg/kg/day (mean 0.12 ± 0.02).
In the remaining four patients (Nos. 1, 3, 6 and 10)
methimazole treatment was withdrawn from 1.9 to
7.0 years after its initiation and no relapses were re-
corded 2.0–2.1 years after its withdrawal. All these four
patients developed, from 0.1 to 0.3 years after methima-
zole withdrawal, a biochemical picture of overt
hypothyroidism and needed replacement treatment with
L-T4, that is now being continued since 1.7–2.0 years.
These four individuals did not significantly differ from
the other ones, either in terms of thyroid function tests
and autoantibody serum levels at HT diagnosis or in
terms of TRAB serum values at GD presentation.
No patients needed non-pharmacological therapies,
such as surgery or radioiodine ablation, during follow-
up.
Discussion
The fluctuations in phenotypic expressions of AITDs,
which may sometimes be observed, have been, in re-
cent years, the theme of editorials [14, 15] and Let-
ters to the Editors [4, 5], that raised interesting
questions about this peculiar aspect of AITDs. All
these comments have regarded a phenomenon that
has been hitherto described almost exclusively by
means of isolated case- reports [7–9]. To the best of
our knowledge, in fact, the study population reported
in the present investigation is the second largest pa-
tient cohort in which the phenomenon of
metamorphic thyroid autoimmunity has been to date
described, after the one by Takasu and Mutsushita
[10]. Moreover, our study is peculiar in that it has
regarded a highly selected population, consisting ex-
clusively of DS young patients.
An evolution from HT to GD is known to be pos-
sibly, although infrequently, observed in the natural
history of children with HT [6]. Those findings sug-
gested that HT and GD are two ends of the AITD
spectrum, from a primarily cell-mediated destruction
of thyroid tissue in HT to TRAB – mediated gland
activation causing GD [7]. A mechanism, which was
guessed to explain the immunological paradigm shift
converting HT to GD, is the possible change in the
biological activity of TRABs, from predominantly
thyroid-blocking antibodies (TBAbs) during the HT
phase to thyroid-stimulating antibodies (TSAbs), when
GD manifests itself [14]. According to this hypothesis,
TSAb emergence after L-T4 therapy might be suffi-
cient to counteract TBAb inhibition [15]. This hypo-
thetic mechanism, however, would not explain why,
in the present study, the conversion from HT to GD
occurred both in the patients who had been treated
with L-T4 and in those who received no treatment.
Moreover, it has to be considered that, in our study,
TRABs had been sought even at diagnosis of HT and
had resulted to be negative in all cases. Therefore,
due to these reasons, the hypothesis of a shift in the
biological activity of TRABs during the time interval
between HT and GD is very unlikely, at least in the
patients of our series.
In this study we have found that one third of our
patients exhibited, after methimazole withdrawal, a
spontaneous change of thyroid function, from hyper-
thyroidism to hypothyroidism. This finding might be,
probably, explained by the hypothesis that the stimu-
latory effects of TRABs in these cases were over-
whelmed by a HT – related severe damage of thyroid
tissue [15]. Such hypothesis seems to be particularly
relevant to our patients considering that our series
consisted exclusively of DS patients, i.e. individuals
who are per se more exposed to the risk of thyroid
function impairment [16–18].
The relatively high number of children with meta-
morphic thyroid autoimmunity recruited for this
study supports the view that DS children might be
particularly prone to manifest over time a phenotypic
metamorphosis from HT to GD [11], although the
pathophysiological bases of this inclination have not
been clarified to date.
Another peculiarity of AITDs in the DS patients of
our study population was that clinical course of GD
was not very severe, as suggested by both the high re-
mission rate during the first cycle of methimazole
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treatment and the absence of relapses after methima-
zole withdrawal. Moreover, the methimazole dosage
requested to maintain biochemical euthyroidism was
low and alternative non – pharmacological therapies
were not needed in any patients of our series. These
findings might suggest that in the present cohort of
DS patients GD showed a milder clinical and bio-
chemical course, an observation which had been
already reported in some previous studies [19, 20].
Finally, in our study population AITDs presented
very early, were not associated with familial anteced-
ents of thyroid disorders and showed no gender pre-
dominance. All these findings suggest that DS
children are per se more exposed to the risk of
AITDs, irrespective of age, gender and familial predis-
position [19, 21–23].
To sum up, although we are aware that the rela-
tively small study population and the retrospective
nature of our study hamper to draw firm conclusions
about the significance of our findings, nevertheless we
believe that this may be a useful contribution to the
specific literature on the metamorphic thyroid
autoimmunity, due to the peculiarities of our study
cohort.
Conclusions
We conclude that: 1) DS children might be incline to
manifest over time a phenotypic metamorphosis from
HT to GD and to subsequently fluctuate from hyper-
thyroidism to hypothyroidism; 2) in DS GD may have
a mild biochemical and clinical course.
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